Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 2229 (LINC02229) is a long intergenic non-coding RNA (lincRNA), a type of autonomously transcribed RNA longer than 200 nucleotides that does not overlap with annotated protein-coding genes[1][3][5]. LincRNAs such as LINC02229 are part of the long non-coding RNA (lncRNA) family and are thought to play regulatory roles in gene expression, chromatin remodeling, and transcription, often with tissue specificity[3][5]. LINC02229 does not encode a protein and its specific biological or disease roles are not well-defined in current literature[1]. There is no evidence to date that LINC02229 serves as a therapeutic target, nor are there descriptions of interacting drugs, mechanisms of action, or its use as a biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Long intergenic non-protein coding RNA 2229 (LINC02229).